ArticleDrug testing and analysis2026
Analytical Challenges in Detecting New Psychoactive Substances in Anti-Doping: A Proof-of-Concept Involving Pentedrone Metabolite.
Article in Drug testing and analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
New psychoactive substances (NPS) have become increasingly prevalent worldwide, posing a growing challenge to public health, forensic science, and doping control. Their structural diversity, rapid emergence, and legal ambiguity complicate both toxicological assessment and analytical detection. Research into the metabolism of these compounds is limited by ethical constraints on administration studies, hindering the development of reference standards. This study presents a methodological approach for the identification and confirmation of 2-amino-1-phenylpentan-1-ol, a metabolite associated with several synthetic cathinones, including pentedrone, α-pyrrolidinopentiophenone (PVP), and N-ethylpentedrone (NEP). The compound was detected in a routine doping control sample using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). In the absence of a commercially available certified reference material (CRM) encompassing all potential isomeric forms, a custom synthesis of the target metabolite was undertaken. The synthesized CRM-enabled unambiguous confirmation of the analyte and its diastereomeric composition, demonstrating the importance of reference compound availability for the accurate interpretation of results in anti-doping analysis. This work highlights both the analytical challenges posed by NPS and the need for continued development of tailored CRMs to support doping control laboratories worldwide.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.